Article
Oncology
Yi-Chieh Chen, Ming-Ju Tsai, Mei-Hsuan Lee, Chia-Yu Kuo, Mei-Chiou Shen, Ying-Ming Tsai, Huang-Chi Chen, Jen-Yu Hung, Ming-Shyan Huang, Inn-Wen Chong, Chih-Jen Yang
Summary: In lung cancer patients with EGFR mutations, daily treatment with 30mg of afatinib as initial therapy showed similar response rates, progression free survival, and overall survival compared to 40mg dose, but significantly fewer serious adverse drug reactions.
Article
Oncology
Ming-Ju Tsai, Jen-Yu Hung, Juei-Yang Ma, Yu-Chen Tsai, Kuan-Li Wu, Mei-Hsuan Lee, Chia-Yu Kuo, Cheng-Hao Chuang, Tai-Huang Lee, Yen-Lung Lee, Chun-Ming Huang, Mei-Chiou Shen, Chih-Jen Yang, Inn-Wen Chong
Summary: This study retrospectively enrolled patients with lung adenocarcinomas harboring EGFR mutations who were treated with first-line afatinib. Patients who received local consolidative therapy (LCT) had significantly longer PFS and OS. Multivariable analysis and propensity score-weighting showed consistent results. This study suggests that LCT may improve clinical outcomes, in terms of PFS and OS, in patients with advanced EGFR-mutant lung adenocarcinomas who are treated with first-line afatinib.
Article
Oncology
Kazuhiko Nakagawa, Ernest Nadal, Edward B. Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin-Yuan Shih, Luis Paz-Ares, Bente Frimodt-Moller, Annamaria H. Zimmermann, Sameera Wijayawardana, Carla Visseren-Grul, Martin Reck
Summary: In patients with EGFR-mutated NSCLC, the combination treatment of erlotinib and ramucirumab (RAM+ERL) demonstrated significant clinical benefits for both ex19del and ex21L858R mutation types, with similar treatment outcomes and tolerability. Baseline TP53 co-mutation was associated with improved outcomes in both mutation subtypes.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu
Summary: This retrospective analysis compared the efficacy of afatinib combined with bevacizumab to erlotinib combined with bevacizumab in the first-line treatment of EGFR-mutated NSCLC, showing no significant difference in objective response rate and disease control rate between the two combination therapies, with diarrhea being more common in the afatinib group.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Paolo Zucchiatti, Giovanni Birarda, Andrea Cerea, Marta S. Semrau, Aliaksandr Hubarevich, Paola Storici, Francesco De Angelis, Andrea Toma, Lisa Vaccari
Summary: This study demonstrates the potential of SEIRA microscopy in detecting subtle secondary structure modifications associated with the binding of Lapatinib to EGFR. By optimizing techniques and data analysis, the researchers successfully identified secondary structure modifications in EGFR related to a few amino acids.
Article
Oncology
Yi Li, Yixuan Qiu, Huihui Li, Ting Luo, Wei Li, Hong Wang, Bin Shao, Biyun Wang, Rui Ge
Summary: The study reported real-world data of pyrotinib plus vinorelbine therapy in HER2+ MBC patients from six institutions in China. The results demonstrated promising effects of this treatment in terms of median progression-free survival, particularly in patients with second-line treatment and without prior lapatinib treatment, as well as in patients with brain metastases.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Christina Nguyen, Manali Phadke, Fang -Yong Li, Joel Neal, Mark A. Lemmon, Zenta Walther, Katerina Politi, Sarah B. Goldberg
Summary: The drug osimertinib has reduced effectiveness in treating the uncommon EGFR mutation ex19del L747_A750>P compared to the common mutation E746_A750del in non-small cell lung cancer patients. The clinical efficacy of osimertinib in treating tumors with L747_A750>P and other uncommon ex19dels is not known.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Ying-Yi Chen, Kuan-Hsun Lin, Yen-Shou Kuo, Yuan-Ming Tsai, Hsu-Kai Huang, Tsai-Wang Huang
Summary: This study investigated the impact of EGFR-TKI in patients with advanced lung adenocarcinoma treated with various therapeutic strategies. The results showed that TKI with lung cancer salvage surgery is the best therapeutic strategy, leading to significantly longer overall survival and extended duration of TKI usage.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
Summary: This study investigated 363 patients with advanced lung adenocarcinoma harboring EGFR mutations and evaluated the efficacy of afatinib, erlotinib, and gefitinib according to mutation type. E19del and L858R mutations were associated with superior progression-free survival and overall survival compared to uncommon mutations. Afatinib showed significantly longer progression-free survival across all EGFR mutation types.
Article
Oncology
Naoyuki Nishiya, Yusuke Oku, Chie Ishikawa, Tsutomu Fukuda, Shingo Dan, Tetsuo Mashima, Masaru Ushijima, Yoko Furukawa, Yuka Sasaki, Keishi Otsu, Tomoko Sakyo, Masanori Abe, Honami Yonezawa, Fumito Ishibashi, Masaaki Matsuura, Akihiro Tomida, Hiroyuki Seimiya, Takao Yamori, Masatomo Iwao, Yoshimasa Uehara
Summary: The derivative of marine alkaloid topoisomerase inhibitor lamellarin N has been shown to provide a new class of EGFR-TKIs that are effective against the C797S mutant EGFR. This represents a potential solution to prevent cross-resistance against known drugs in this class.
Article
Cell Biology
Chun-Hau Dai, Li-Rong Zhu, Yi Wang, Xing-Ping Tang, Yong-Jie Du, Yong-Chang Chen, Jian Li
Summary: This study demonstrated that celastrol synergistically induced paraptosis with afatinib in NSCLC cells, independent of apoptosis and autophagy induction. The combination of celastrol and afatinib also effectively suppressed the growth of H23 cell xenograft tumors in vivo. These findings suggest that the combination of afatinib and celastrol may be a promising therapeutic strategy to overcome intrinsic afatinib resistance in NSCLC cells.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Review
Oncology
Wei Yang, Yansong Lu, Ze Wu, Jun Niu
Summary: This case report describes a patient with metastatic non-small cell lung cancer who developed afatinib-induced toxic epidermal necrosis (TEN). The effects of afatinib were evaluated using the ALDEN algorithm. Treatment with corticosteroids resulted in significant improvement and complete remission of the clinical symptoms.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Takayuki Takahashi, Hideyuki Terazono, Takayuki Suetsugu, Hideki Sugawara, Junko Arima, Mina Nitta, Toru Tanabe, Kayu Okutsu, Ryuji Ikeda, Keiko Mizuno, Hiromasa Inoue, Yasuo Takeda
Summary: Afatinib, a second-generation EGFR-tyrosine kinase inhibitor, is used to treat NSCLC with EGFR mutation. Monitoring its trough plasma concentration can help predict adverse effects and support effective therapy. Higher plasma concentrations of afatinib are associated with adverse events, indicating a need for potential dose reduction to maintain quality of life.
Article
Polymer Science
Tahir Mehmood, Rath Pichyangkura, Chatchai Muanprasat
Summary: This study demonstrates that chitosan oligosaccharide can reduce the diarrhea induced by afatinib and regulate the tight junctions and chloride secretion in intestinal epithelial cells by activating AMPK. This study provides a promising natural polymer-derived compound for further development of treatment for afatinib-associated diarrhea.
Article
Oncology
Chung-Fu Lin, Szu-Yu Liu, Tzu-Kun Lo, Julia Yu-Yun Lee, Po-Lan Su
Summary: Tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutant NSCLC, but can cause severe adverse events. We report a case of DRESS after afatinib treatment, successfully managed with erlotinib.